论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
Exportin-T 顺利获得 PI3K/AKT/mTOR 信号通路促进乳腺癌进展
Authors Hou Z, Ma W, Ren D, Shen N, Bi W, Guo M, Li X, Wang Y , Jia H
Received 16 January 2025
Accepted for publication 16 May 2025
Published 21 May 2025 Volume 2025:18 Pages 6467—6481
DOI http://doi.org/10.2147/JIR.S512905
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Ning Quan
Zhichao Hou,1 Wenxia Ma,2 Dongliang Ren,1 Ningning Shen,2 Weilin Bi,1 Meiqin Guo,1 Xinzheng Li,1 Yanhong Wang,3 Hongyan Jia4
1Department of Breast Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China; 2Department of Pathology, The Second Hospital of ShanXi Medical University, Tai Yuan, People’s Republic of China; 3Department of Microbiology and Immunology, Shanxi Medical University, Taiyuan, People’s Republic of China; 4Department of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China
Correspondence: Hongyan Jia, Department of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, People’s Republic of China, Email swallow_jhy@163.com
Purpose: Breast cancer (BC) is the most common malignant tumor in women. Exportin-T (XPOT) which is a member of the karyopherin -β family has been identified as a prognostic biomarker in various cancers, but its role in BC remains inadequately understood. This study aims to investigate the clinical characterization and molecular mechanism of XPOT in BC.
Material and Methods: A retrospective RNA-seq data analysis based on a cohort of 966 BC patients from The Cancer Genome Atlas database (TCGA) and 1904 patients from the Molecular Taxonomy of Breast Cancer International Consortium database was conducted for analyzing the correlation between XPOT expression and BC clinical pathological features. In addition, small interfering RNA transfection was used to downregulate XPOT expression in MDA-MB-468/231 cell lines followed by cell proliferation assessed via Cell Counting Kit-8 assays, meanwhile, BC cell migration and invasion capabilities were measured using Transwell test. Expression levels of CDK4/6 and key proteins in the PI3K/Akt/mTOR signaling pathway were assessed using Western blotting.
Results: We found that XPOT was enriched in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, larger tumor size, and cases with increased lymph node metastasis BC. XPOT was identified as a potential biomarker for the basal subtype of BC and a prognostic factor for the overall survival of patients with BC. Furthermore, XPOT promoted the proliferation and invasion of BC cells, likely through activation of the PI3K/AKT/mTOR signaling pathway, which in turn to upregulate cyclin D and CDK4/6 to drive tumor progression.
Conclusion: Our findings indicate that XPOT overexpression is associated with poor clinical characteristics and poor prognosis in BC, promoting disease progression by activating PI3K/AKT/mTOR pathway. These findings highlight XPOT as a potential therapeutic target in BC.
Keywords: breast cancer, exportin-T, cell proliferation, PI3K/AKT/mTOR signaling, prognosis biomarkers